The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis.
Open Access
- 1 January 1999
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 43 (1), 113-118
- https://doi.org/10.1093/jac/43.1.113
Abstract
Since the efficacy of β-lactams against pathogens such as methicillin-susceptible Staphylococcus aureus (MSSA) is related to the time for which serum drug concentrations exceed the MIC for the pathogen, administration of anti-staphylococcal β-lactams by continuous infusion may provide a more suitable means of drug delivery than intermittent dosing. To assess the clinical efficacy of continuous-infusion therapy, we reviewed the outcomes for 20 consecutive patients with proven serious MSSA sepsis (three with endocarditis, ten osteomyelitis, one endocarditis plus osteomyelitis and six deep abscess) treated with continuous-infusion flucloxacillin (8–12 g/day). Patients initially receiving routine intermittent-dose flucloxacillin therapy were changed to continuous-infusion flucloxacillin (mean duration 29 days; range 4–60 days) for completion of their treatment course. In the majority of cases this was given at home. Serum flucloxacillin concentrations during continuous-infusion flucloxacillin 12 g/day were 11.5–>40 mg/L (ten patients) and those during continuous-infusion flucloxacillin 8 g/day were 8–>40 mg/L (five patients), these concentrations being well above the expected MIC of flucloxacillin for MSSA. Continuous-infusion flucloxacillin was well tolerated by most patients, and 14/17 patients (82%) who completed their course of continuous-infusion flucloxacillin were judged clinically and microbiologically cured at long-term follow-up (mean 67 weeks; range 4–152 weeks). These preliminary data suggest that, following initial intermittent-dose flucloxacillin therapy, continuous-infusion flucloxacillin is an effective treatment option for serious MSSA sepsis, and forms a feasible and possibly preferable alternative to glycopeptides when considering home-based parenteral therapy for these infections. Further studies are needed to identify whether continuous-infusion flucloxacillin can entirely replace intermittent-dose therapy for such infections.Keywords
This publication has 19 references indexed in Scilit:
- The Pharmacodynamics of β‐LactamsClinical Infectious Diseases, 1998
- Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USAEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Beta-Lactam Antibiotics: Is Continuous Infusion The Preferred Method of Administration?Annals of Pharmacotherapy, 1995
- Risk factors for development of flucloxacillin associated jaundice.BMJ, 1993
- Continuous infusion of beta-lactam antibioticsAntimicrobial Agents and Chemotherapy, 1992
- Liver damage from flucloxacillin, cloxacillin and dicloxacillinJournal of Hepatology, 1992
- CONTINUOUS INFUSION OF CEFTAZIDIME IN CYSTIC FIBROSISThe Lancet, 1989
- CURE OF PSEUDOMONAS AERUGINOSA INFECTION IN NEUTROPENIC PATIENTS BY CONTINUOUS INFUSION OF CEFTAZIDIMEThe Lancet, 1988
- Pulse Dosing Versus Continuous Infusion of AntibioticsClinical Pharmacokinetics, 1988
- Continuous-infusion ampicillin therapy of enterococcal endocarditis in ratsAntimicrobial Agents and Chemotherapy, 1987